These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

611 related items for PubMed ID: 27790809

  • 1. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
    Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbaek L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L.
    Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
    [Abstract] [Full Text] [Related]

  • 2. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, Mann DL, Whellan DJ, Kiernan MS, Felker GM, McNulty SE, Anstrom KJ, Shah MR, Braunwald E, Cappola TP, NHLBI Heart Failure Clinical Research Network.
    JAMA; 2016 Aug 02; 316(5):500-8. PubMed ID: 27483064
    [Abstract] [Full Text] [Related]

  • 3. Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.
    Hamad F, Elnour AA, Elamin A, Mohamed S, Yousif I, Don J, Abdi S, Al Amoodi A, Fathelrahman AI, Gnana K, Alanzi F, Abubakar AB, Magboul SM, Ahmed SA, Sadeq A.
    Curr Diabetes Rev; 2021 Aug 02; 17(3):280-292. PubMed ID: 32867644
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, Perticone M, Sesti G, Perticone F.
    Endocrine; 2017 Sep 02; 57(3):464-473. PubMed ID: 27830456
    [Abstract] [Full Text] [Related]

  • 5. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
    Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard TW, Kumme A, Møller JE, Videbæk L, Kistorp C, Gustafsson I, Tarnow L, Flyvbjerg A.
    BMJ Open; 2014 May 20; 4(5):e004885. PubMed ID: 24844271
    [Abstract] [Full Text] [Related]

  • 6. Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE.
    Liang B, Gu N.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):106. PubMed ID: 32631360
    [Abstract] [Full Text] [Related]

  • 7. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, Maratou E, Georgiou D, Andreadou I, Parissis J, Triantafyllidi H, Lekakis J, Iliodromitis E, Dimitriadis G, Ikonomidis I.
    Cardiovasc Diabetol; 2018 Jan 08; 17(1):8. PubMed ID: 29310645
    [Abstract] [Full Text] [Related]

  • 8. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
    Nielsen R, Jorsal A, Tougaard RS, Rasmussen JJ, Schou M, Videbaek L, Gustafsson I, Faber J, Flyvbjerg A, Wiggers H, Tarnow L, Kistorp C.
    Diabetes Obes Metab; 2020 Nov 08; 22(11):2141-2150. PubMed ID: 32627271
    [Abstract] [Full Text] [Related]

  • 9. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
    McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, Lewsey JD, Krum H, VIVIDD Trial Committees and Investigators.
    JACC Heart Fail; 2018 Jan 08; 6(1):8-17. PubMed ID: 29032139
    [Abstract] [Full Text] [Related]

  • 10. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
    Redouane B, Greene SJ, Fudim M, Vaduganathan M, Ambrosy AP, Sun JL, DeVore AD, McNulty SE, Mentz RJ, Hernandez AF, Felker GM, Cooper LB, Borlaug BA, Velazquez EJ, Margulies KB, Sharma A.
    Circ Heart Fail; 2020 May 08; 13(5):e006758. PubMed ID: 32362166
    [Abstract] [Full Text] [Related]

  • 11. Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.
    Nielsen R, Jorsal A, Iversen P, Tolbod LP, Bouchelouche K, Sørensen J, Harms HJ, Flyvbjerg A, Tarnow L, Kistorp C, Gustafsson I, Bøtker HE, Wiggers H.
    J Nucl Cardiol; 2019 Apr 08; 26(2):585-597. PubMed ID: 28770459
    [Abstract] [Full Text] [Related]

  • 12. Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
    Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, Fossler M, Davila-Roman VG, Russell SD, Gropler RJ.
    JACC Heart Fail; 2016 Jul 08; 4(7):559-566. PubMed ID: 27039125
    [Abstract] [Full Text] [Related]

  • 13. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB, Jazet IM, Westenberg JJM, van Eyk HJ, Paiman EHM, Smit JWA, Lamb HJ.
    Cardiovasc Diabetol; 2019 Apr 30; 18(1):55. PubMed ID: 31039778
    [Abstract] [Full Text] [Related]

  • 14. Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events.
    Tougaard RS, Jorsal A, Tarnow L, Hansson NH, Kistorp C, Schou M, Nielsen R, Flyvbjerg A, Videbaek L, Mølgaard H, Nielsen JC, Gustafsson I, Wiggers H.
    Scand Cardiovasc J; 2020 Oct 30; 54(5):294-299. PubMed ID: 32292074
    [Abstract] [Full Text] [Related]

  • 15. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, Zhang J.
    Cardiovasc Diabetol; 2021 Jan 25; 20(1):25. PubMed ID: 33494751
    [Abstract] [Full Text] [Related]

  • 16. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES, Miller L, Patel AN, Anderson RD, Mendelsohn FO, Traverse J, Silver KH, Shin J, Ewald G, Farr MJ, Anwaruddin S, Plat F, Fisher SJ, AuWerter AT, Pastore JM, Aras R, Penn MS.
    Eur Heart J; 2015 Sep 01; 36(33):2228-38. PubMed ID: 26056125
    [Abstract] [Full Text] [Related]

  • 17. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD, Van Linthout S, Westermann D, Lindhorst R, Sandek A, Ernst S, Bobenko A, Kasner M, Spillmann F, González A, López B, Ravassa S, Pieske B, Paulus WJ, Díez J, Edelmann F, Tschöpe C.
    Eur J Heart Fail; 2018 Mar 01; 20(3):460-470. PubMed ID: 28891228
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial.
    Nauck MA, Tornøe K, Rasmussen S, Treppendahl MB, Marso SP, LEADER Publication Committee on behalf of the LEADER Trial Investigators.
    Diab Vasc Dis Res; 2018 Sep 01; 15(5):465-468. PubMed ID: 29947247
    [Abstract] [Full Text] [Related]

  • 19. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
    Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW.
    Cardiovasc Diabetol; 2021 Jan 07; 20(1):12. PubMed ID: 33413428
    [Abstract] [Full Text] [Related]

  • 20. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
    Bizino MB, Jazet IM, de Heer P, van Eyk HJ, Dekkers IA, Rensen PCN, Paiman EHM, Lamb HJ, Smit JW.
    Diabetologia; 2020 Jan 07; 63(1):65-74. PubMed ID: 31690988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.